#JimSchraidt follows as second speaker for the second day #PatientPerspectives #AUA 24 . While a Board Member for ZERO Prostate Cancer and involved with AnCan Foundation he emphasizes he is presenting his own #prostatecancer story - today entitled “A Mental Health Journey.” Amer. Urol. Assn. #AUA …

Today! Come by #AUA2024 Patient perspectives at 3:15 to be inspired by #kidneycancer patient Carie Gort and learn how she’s managing treatment related diarrhea through dietary changes.

#kidneycancer patient advocates at Fox Chase Cancer Center Department of Urology dinner. Many thanks to Alexander Kutikov MD for recognizing the value of pt voice at #AUA24 .

Tracie Titus follows Tom Hulsey at #PatientPerspectived #AUA 24 . Begins her talk with her husband’s diagnosis - #KidneyCancer and offers insight into his exploration of treatments and management options. See kccure.org for more information. Amer. Urol. Assn. #AUA …

Two major health conditions, four different specialists, three health portals, and ONE major decision. Tracie Titus knocks it out of the park illustrating the navigational burden #kidneycancer pts face. #AUA2024

#AUA2024 patient perspectives! Today at 1:00! Come see Tracie Titus share about navigating comorbidities in RCC!

⚡️Proud to have finally published this paper with Pedro C Barata, MD MSc FACP and hugely appreciate Rana McKay’s unwavering mentorship and advice! Huge thanks to Caris Life Sciences and chadi nabhan MD, MBA, FACP!

⚡️We attempt to understand genomic and transcriptional differences between variant histologies of…

Kidney Cancer IKCC Kidney Cancer Many thanks to the Kidney Cancer and the organizers for the invitation, honored by power for the opportunity to tell you about the vision of @fnalcer and its work with kidney cancer patients

The IKCS: Europe emphasized patient advocacy, focusing on program implementation for patient and organization support—a critical step for improved healthcare. #PatientAdvocacy
Kidney Cancer Michael Staehler Salvatore La Rosa Laurence Albiges Cris Dena Battle Ignacio Duran #IKCSEU24 …

A huge thank you to the #IKCSEU24 Scientific Planning Committee for their dedication and hard work in delivering an outstanding program. Your collective expertise has made a remarkable impact on the kidney cancer community.

Kidney Cancer Michael Staehler Salvatore La Rosa Laurence Albiges…

The rules are clear and the panel is ready to be grilled! #woodfire is about to start at #IKCSEU24 . Remembering Chris Wood and having an engaging discussion!

Congratulations to Lisa Henske at Brigham and Women's Hospital - KCCure’s 2024 #chromophobe #kidneycancer grant winner. We are excited to see this promising research move forward. Your work is bringing hope to many! kccure.org/2024/04/chromo…

Phenomenal 'debate' session highlighting the challenges in IMDC favorable risk, and strategies for choosing a comparator arm for future trials. Tremendously thoughtful discussions from Cris Ignacio Duran Martin Voss and Dr. Bernard Escudier #IKCSEU24 Kidney Cancer

A mother fighting to stay alive for her young children. A young woman sharing her experience with debilitating side effects. Real stories of people living with #kidneycancer . Thank you Kidney Cancer for hosting this panel at #IKCSEU24 . Thank you to these brave pts for sharing.

Subsequent treatment of control arm of adjuvant trials is causing controversy due to subsequent IO access. In the +ve renal & bladder studies 81%/48% and ~62%/~36% received further therapy/IO respectively.However the figure below shows these analysis are time dependant & complex

Hear from Drs. Sumanta K. Pal, MD, FASCO, Pedro C Barata, MD MSc FACP, McDermott, & Tian Zhang, MD, MHS how to use team-based strategies for mitigating & managing adverse events to allow your patients with #RCC to continue to receive optimal care! Developed with PeerView: bit.ly/4coeVh0  #GU24 #MedEd

At #JSMO with 3 controversies from ASCOGU 1) The -ve OS adjuvant pembro data in UC questions this approach more broadly. Censoring ++ on KM curve though. 2) More data needed to prove atezo is active with cabo in CRPC. 3)Ipi/nivo looks as good as anything else in good risk M1 RCC

Wow. Update from Dr. Tannir MD Anderson Cancer Center presenting 8 year f/u for CM214. For patients who responded to nivo+ipi, half are still responding 8 years later. Also interesting OS for IMDC favorable risk. OncLive.com OncoAlert UroToday.com KidneyCAN Kidney Cancer

#RaquibHannan UTSW Radiation Oncology UTSW Simmons Cancer Center showcases the ECOG-ACRIN Cancer Research Group #SOAR trial — open now and available for all NCI CTEP Clinical Research sites! #GU24 OncoAlert

Learn from Drs. Sumanta K. Pal, MD, FASCO, Pedro C Barata, MD MSc FACP, McDermott, & Tian Zhang, MD, MHS how to use team-based strategies for mitigating & managing adverse events to allow your patients with #RCC to continue to receive optimal care! 1/25 at 6:00 PM PST. With @KCCure! bit.ly/RCC24T #GU24